DDR1 and neoplasm: Underpinning the mechanisms of how DDR1/BCR-ABL targeting works against KRAS-mutant tumors requires further investigation may involve limiting the stimuli for cell adhesion, survival, anti-apoptotic, and proliferation factors, all of which may co-operate with mutant KRAS to exhibit tumor aggressivity.